argenx SEBSP:A1RG34 81 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates BSP:A1RG34 with a GF Score™ of 81/100 and a GF Value™ of R$310.30 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 960 Biotechnology companies, argenx SE ranks better than 79.37% on this metric.
The historical rank and industry rank for argenx SE's OCF Margin % or its related term are showing as below:
BSP:A1RG34'
s OCF Margin % Range Over the Past 10 Years
Min: -966.13 Med: -67.32 Max: 193.25
Current: 14.88
During the past 13 years, the highest OCF Margin % of argenx SE was 193.25%. The lowest was -966.13%. And the median was -67.32%.
BSP:A1RG34's OCF Margin % is ranked better than 79.37% of 960
companies
in the Biotechnology industry
Industry Median: -68.59
vs BSP:A1RG34: 14.88
argenx SE OCF Margin % Related Terms
argenx SE OCF Margin % Historical Data
* Premium members only.
The historical data trend for argenx SE's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:A1RG34 vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, argenx SE's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's OCF Margin % distribution charts can be found below:
* The bar in red indicates where argenx SE's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (BSP:A1RG34) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on argenx SE and its competitors. According to the industry distribution chart, argenx SE ranks #198 out of 960 companies in the Biotechnology industry, placing it in the top 20.6%.
Is argenx SE's OCF Margin % too high?
argenx SE's current OCF Margin % is 0.00%. Based on the distribution chart, argenx SE ranks #198 out of 960 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, argenx SE has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #198 out of 960 companies for OCF Margin %. This places argenx SE in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on argenx SE and its competitors. argenx SE's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (BSP:A1RG34) is currently considered Significantly Undervalued. The stock's GF Value™ is R$310.30, compared to a current price of R$192.55 — trading 37.9% below its estimated fair value. The current OCF Margin % is 0.00%. argenx SE's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For argenx SE (BSP:A1RG34), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (BSP:A1RG34) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of R$192.55 is trading 37.9% below its estimated GF Value™ of R$310.30.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for BSP:A1RG34:
OCF Margin %: 0.00%
GF Value™: R$310.30 vs. price of R$192.55 (37.9% below fair value)
No single metric tells the full story. See the BSP:A1RG34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
81GF Score
Get the complete analysis for BSP:A1RG34
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:A1RG34 has been successfully added to your 
